[HTML][HTML] A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy …
K Yamada, H Aono, Y Hosomi, H Okamoto… - European Journal of …, 2015 - Elsevier
Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …
Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in …
K Yamada, K Takayama, S Kawakami… - Japanese journal of …, 2013 - academic.oup.com
Objective Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer
harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no …
harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of …
Y Matsumoto, M Maemondo, Y Ishii, K Okudera… - Lung Cancer, 2014 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are
particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR …
particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer
Objectives In 2008, we initiated a prospective study to explore the frequency and predictive
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non–small-cell lung cancer in the …
GM Clark, DM Zborowski, P Santabárbara, K Ding… - Clinical lung cancer, 2006 - Elsevier
Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
[HTML][HTML] Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german …
CP Schneider, D Heigener, K Schott-von-Römer… - Journal of Thoracic …, 2008 - Elsevier
Introduction Relationships between clinical outcomes and epidermal growth factor receptor
(EGFR)-related tumor markers were investigated in patients with advanced non-small cell …
(EGFR)-related tumor markers were investigated in patients with advanced non-small cell …
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study
DR Choi, DH Lee, CM Choi, SW Kim, C Suh… - Anticancer …, 2011 - ar.iiarjournals.org
Background: This phase II study evaluated efficacy of first-line erlotinib therapy for chemo-
naïve patients with non-small cell lung cancer (NSCLC) by their clinicopathological and/or …
naïve patients with non-small cell lung cancer (NSCLC) by their clinicopathological and/or …